Grünenthal hires ex-AstraZeneca as CCO; debuts promissory note

1 September 2017

German family-owned pharma company Grünenthal Group today announces that Mark Fladrich has taken office as new chief commercial officer (CCO).

Grünenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation headquartered in Aachen, Germany. In his last appointment Mr Fladrich served as area vice President, Southern and Western Europe for Anglo-Swedish drug major AstraZeneca (LSE: AZN).

The 57-year-old Australian brings a broad variety of expertise to Grünenthal – from in-market knowledge to regional and global sales and marketing roles. Mr Fladrich has almost 30 years of experience in the pharmaceutical industry. This includes large country management roles with AstraZeneca in Germany and Australia/New Zealand with over $1 billion of sales revenue in each country under his responsibility. He was also globally responsible for all Phase III products and promoted brands and for providing commercial input into R&D for all stages of clinical development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK